Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Free Cash Flow (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Free Cash Flow for 5 consecutive years, with $53.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 184.91% year-over-year to $53.3 million, compared with a TTM value of $136.4 million through Dec 2025, up 436.82%, and an annual FY2025 reading of $136.4 million, up 436.82% over the prior year.
  • Free Cash Flow was $53.3 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $33.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $62.0 million in Q3 2022 and bottomed at -$40.2 million in Q1 2021.
  • Average Free Cash Flow over 5 years is $2.7 million, with a median of $813000.0 recorded in 2024.
  • The sharpest move saw Free Cash Flow tumbled 113.31% in 2024, then skyrocketed 1564.36% in 2025.
  • Year by year, Free Cash Flow stood at -$19.1 million in 2021, then soared by 39.67% to -$11.5 million in 2022, then skyrocketed by 136.98% to $4.3 million in 2023, then soared by 337.9% to $18.7 million in 2024, then surged by 184.91% to $53.3 million in 2025.
  • Business Quant data shows Free Cash Flow for KNSA at $53.3 million in Q4 2025, $33.1 million in Q3 2025, and $27.8 million in Q2 2025.